Aligos Therapeutics Inc
$ 7.09
2.16%
24 Feb - close price
- Market Cap 43,628,900 USD
- Current Price $ 7.09
- High / Low $ 7.25 / 6.85
- Stock P/E N/A
- Book Value 11.67
- EPS -13.54
- Next Earning Report 2026-03-09
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.55 %
- ROE -1.42 %
- 52 Week High 18.61
- 52 Week Low 3.76
About
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California.
Analyst Target Price
$68.20
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-06 | 2025-05-05 | 2025-03-10 | 2024-11-06 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-03-09 |
| Reported EPS | -3.04 | -1.53 | -2.1133 | -13.1 | -3.07 | 0.03 | -0.22 | -0.22 | -0.41 | -0.43 | -0.53 | -0.51 |
| Estimated EPS | -0.25 | -0.24 | -3.1533 | -3.67 | -2.16 | -0.16 | -0.19 | -0.27 | -0.47 | -0.49 | -0.48 | -0.47 |
| Surprise | -2.79 | -1.29 | 1.04 | -9.43 | -0.91 | 0.19 | -0.03 | 0.05 | 0.06 | 0.06 | -0.05 | -0.04 |
| Surprise Percentage | -1116% | -537.5% | 32.9813% | -256.9482% | -42.1296% | 118.75% | -15.7895% | 18.5185% | 12.766% | 12.2449% | -10.4167% | -8.5106% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-09 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -2.09 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALGS
2026-02-23 13:35:37
Aligos Therapeutics announced positive data from two presentations at CROI 2026, highlighting their lead candidates for chronic hepatitis B virus (HBV) infection and a pan-coronavirus protease inhibitor. The data showcased promising results for pevifoscorvir sodium in HBV patients and the pharmacokinetics of ALG-097558 in individuals with hepatic and renal impairment. These presentations underscore Aligos's progress in developing best-in-class therapies for viral diseases.
2026-02-23 13:14:00
Aligos Therapeutics, Inc. announced positive results from its CROI presentations on pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection and ALG-097558, a pan-coronavirus protease inhibitor. The data showed high viral suppression for pevifoscorvir sodium and detailed pharmacokinetics for ALG-097558 in patients with hepatic and renal impairment. Aligos continues to advance its research in liver and viral diseases, with the full presentation details to be available on their website.
2026-02-23 13:07:12
Aligos Therapeutics announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI). The presentations detailed results from a Phase 1 monotherapy study of pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection, and pharmacokinetic data for ALG-097558, a pan-coronavirus protease inhibitor, in participants with hepatic and renal impairment. Aligos is advancing both programs, with ALG-097558 having received federal funding for its development.
2026-02-23 12:35:36
Aligos Therapeutics reported positive clinical data at CROI 2026 for two of its programs. The data included high viral suppression from a Phase 1 monotherapy study of pevifoscorvir sodium for chronic hepatitis B and pharmacokinetics data for ALG-097558, a pan-coronavirus protease inhibitor, in patients with hepatic and renal impairment. These presentations highlight the company's ongoing progress in developing therapies for liver and viral diseases.
2026-02-22 12:15:23
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biotechnology company focused on developing therapies for liver and viral diseases, with a primary focus on chronic hepatitis B virus (HBV), obesity, and metabolic dysfunction-associated steatohepatitis (MASH). The company's lead program is pevifoscorvir sodium for HBV, currently in a Phase 2 study called B-SUPREME, and it also has ALG-055009 in development for obesity and MASH. Aligos regularly presents its clinical and preclinical data at scientific conferences and through SEC filings, highlighting its commitment to advancing new treatments in areas of high unmet medical need.
2026-02-21 11:36:50
Aligos Therapeutics will host a virtual Key Opinion Leader (KOL) event on July 18, 2024, to discuss the positive Phase 1b data for ALG-000184 in treating chronic hepatitis B (CHB). The event will feature Dr. Mark Sulkowski and cover the unmet needs in CHB, the current treatment landscape, and future development plans for ALG-000184, which has shown significant viral suppression and received positive feedback from the FDA regarding its regulatory pathway. Aligos' CEO, Lawrence Blatt, emphasized the molecule's potential for superiority over existing treatments.
